Insider trading

Period: 120 months Stock: ALKS Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

163 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

163 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

163 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

163 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
163 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
163 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

163 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
1 Sep 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$422.87K 9,000 at 46.99
12.1%
Planned (10b5-1)
17 Aug 2026
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan 2×
$372.94K 7,576 at 49.23
6.9%
Planned (10b5-1)
3 Aug 2026
Sold at will
$2.24M 44,472 at 50.35
74.3%
Sold half or more
3 Aug 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$437.22K 9,000 at 48.58
11.5%
Planned (10b5-1)
6 Jul 2026
Gaffin David Joseph EVP, CLO, Alkermes, Inc.
Sold on a plan
$109.90K 2,034 at 54.03
0.9%
Planned (10b5-1)
1 Jul 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan 2×
$463.62K 9,000 at 51.51
10.9%
Planned (10b5-1)
1 Jun 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$375.04K 9,000 at 41.67
10.4%
Planned (10b5-1)
29 May 2026
Parisi Samuel Joseph VP, Finance (Interim PAO)
Sold at will
$687.01K 16,217 at 42.36
67.8%
Sold half or more
1 May 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$300.56K 9,000 at 33.40
10.0%
Planned (10b5-1)
1 Apr 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$319.60K 9,000 at 35.51
9.5%
Planned (10b5-1)
2 Mar 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$267.49K 9,000 at 29.72
9.1%
Planned (10b5-1)
2 Mar 2026
Parisi Samuel Joseph VP, Finance (Interim PAO)
Sold on a plan
$201.81K 6,890 at 29.29
47.2%
Planned (10b5-1)
2 Mar 2026
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$180.00K 6,000 at 30.00
5.2%
Planned (10b5-1)
2 Feb 2026
Cooke Shane Director
Sold on a plan 2×
$2.12M 61,200 at 34.57
37.1%
Planned (10b5-1)
2 Feb 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan 2×
$305.38K 9,000 at 33.93
13.5%
Planned (10b5-1)
8 Jan 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$150.01K 5,000 at 30.00
7.5%
Planned (10b5-1)
2 Jan 2026
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$112.00K 4,000 at 28.00
6.1%
Planned (10b5-1)
3 Dec 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$112.45K 3,748 at 30.00
5.4%
Planned (10b5-1)
1 Dec 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$117.20K 4,000 at 29.30
5.7%
Planned (10b5-1)
3 Nov 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$273.44K 9,000 at 30.38
11.4%
Planned (10b5-1)
15 Oct 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$283.78K 9,000 at 31.53
10.9%
Planned (10b5-1)
10 Jun 2025
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$103.65K 3,334 at 31.09
3.7%
Planned (10b5-1)
9 Jun 2025
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$106.49K 3,333 at 31.95
3.6%
Planned (10b5-1)
25 Feb 2025
Parisi Samuel Joseph VP, Finance (Interim PAO)
Sold on a plan
$131.98K 3,743 at 35.26
32.7%
Planned (10b5-1)
13 Feb 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan 2×
$5.13M 144,419 at 35.53
71.4%
Sold half or more
12 Feb 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan 2×
$6.72M 204,921 at 32.78
78.0%
Sold half or more
30 Jan 2025
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$3.23M 100,918 at 32.05
69.5%
Sold half or more
9 Dec 2024
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$1.96M 61,151 at 32.07
56.2%
Sold half or more
5 Dec 2024
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$290.46K 9,221 at 31.50
13.4%
Planned (10b5-1)
4 Dec 2024
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$441.55K 14,349 at 30.77
17.2%
Planned (10b5-1)
27 Nov 2024
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$151.81K 5,208 at 29.15
7.9%
Planned (10b5-1)
11 Nov 2024
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$1.77M 58,996 at 30.08
41.5%
Planned (10b5-1)
6 Nov 2024
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold on a plan
$309.17K 10,471 at 29.53
9.5%
Planned (10b5-1)
18 Mar 2024
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$292.74K 10,417 at 28.10
13.6%
Planned (10b5-1)
30 May 2023
Nichols Christian Todd SVP, Chief Commercial Officer
Sold on a plan
$784.86K 27,134 at 28.93
39.8%
Planned (10b5-1)
9 May 2023
Wysenski Nancy Director
Sold on a plan
$1.29M 41,250 at 31.24
72.3%
Sold half or more
14 Nov 2022
Daglio David Angelo Jr. Director · indirect
Bought
$815.73K 35,000 at 23.31
77.8%
First buy on file
21 Jun 2022
Nichols Christian Todd SVP, Chief Commercial Officer
Sold, plan not stated
$211.20K 7,474 at 28.26
26.2%
17 May 2022
LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc.
Sold, plan not stated
$1.46M 50,000 at 29.15
17.7%
10 May 2022
LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc.
Sold, plan not stated
$680.38K 25,000 at 27.22
9.7%
6 May 2022
POPS RICHARD F Director and CEO, Alkermes plc
Sold, plan not stated
$2.61M 93,747 at 27.85
8.8%
5 May 2022
POPS RICHARD F Director and CEO, Alkermes plc
Sold, plan not stated 2×
$7.11M 253,510 at 28.03
21.2%
3 May 2022
LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc.
Sold, plan not stated
$715.42K 25,000 at 28.62
9.7%
2 May 2022
Cooke Shane Director
Sold, plan not stated
$292.33K 10,000 at 29.23
10.0%
25 Apr 2022
Cooke Shane Director
Sold, plan not stated
$278.85K 10,000 at 27.88
10.0%
20 Apr 2022
Jackson Blair Curtis EVP, Chief Operating Officer
Sold, plan not stated
$1.48M 49,999 at 29.61
36.3%
18 Apr 2022
Cooke Shane Director
Sold, plan not stated
$288.75K 10,000 at 28.88
10.0%
11 Apr 2022
Cooke Shane Director
Sold, plan not stated
$292.60K 10,000 at 29.26
10.0%
4 Apr 2022
Cooke Shane Director
Sold, plan not stated
$281.85K 10,000 at 28.18
10.0%
23 Feb 2022
Hopkinson Craig C. EVP R&D, Chief Medical Officer
Sold, plan not stated
$296.65K 11,983 at 24.76
40.0%
Showing 1–50 of 163. Page 1 of 4 Older →